Medtronic’s Resolute Integrity stent tops Abbott’s Xience in Propel all-comers study Results from the Propel all-comers trial comparing Medtronic‘s (NYSE:MDT) Resolute Integrity drug-eluting stent showed it to be superior to the Xience stent made by rival Abbott (NYSE:ABT). The 1-year study followed 800 patients from the Propel trial who were treated with the Resolute Integrity device, […]
American College of Cardiology Conference (ACC)
Edwards Lifesciences hits all-time high on Sapien 3 study
Shares in Edwards Lifesciences (NYSE:EW) hit an all-time high yesterday after the company reported strong 1-year data for its Sapien 3 replacement heart valve over the weekend. Results from the Partner II trial from 1,077 intermediate-risk patients showed that the Sapien 3 beat surgical valve replacement across a variety of safety endpoints, Irvine, Calif.-based Edwards said at […]
Boston Scientific halts EU sales of next-gen Watchman FLX anti-stroke device
Boston Scientific (NYSE:BSX) reportedly halted European sales of its the next generation of its anti-stroke device, the Watchman FLX, after receiving reports of device embolization. Spokeswoman Trish Backes told TCTMD that there were 6 device embolizations in 207 (2.9%) European implantations of the Watchman FLX, an implant that designed to occlude the heart’s left atrial […]
Boston Scientific’s Synergy stent at 2 years | ACC 2016 roundup
Evolve II: 2-year data for Boston Scientific’s Synergy stent Boston Scientific‘s (NYSE:BSX) Synergy stent showed non-inferiority to its Promus Element Plus device after 12 months, according to data from the Evolve II trial presented yesterday at the annual conference of the American College of Cardiology. The Synergy stent’s bioresorbable polymer coating is designed to dissolve completely […]
Fire & Ice: Medtronic’s Arctic Front ablation catheter as good as BioSense Webster’s ThermoCool | ACC 2016
Results from a clinical trial presented today at the annual meeting of the American College of Cardiology showed that the Arctic Front ablation catheter made by Medtronic (NYSE:MDT) is noninferior to Johnson & Johnson (NYSE:JNJ) subsidiary BioSense Webster’s ThermoCool device in treating atrial fibrillation. The Fire & Ice study compared Arctic Front’s cryoballoon ablation technique with the […]
Medtronic touts more early data from drug-filled stent study | ACC 2016
Medtronic (NYSE:MDT) yesterday touted early data from a clinical study of its drug-filled stent aimed at winning CE Mark approval in the European Union. The DFS is built using the Fridley, Minn.-based medical device giant’s Resolute Integrity and Resolute Onyx stents, using its “continuous sinusoid” and CoreWire technologies. It’s made with a “tri-layer” wire design in which the innermost […]
Edwards Lifesciences touts intermediate-risk data for Sapien devices | ACC 2016
Data from a large trial of the Sapien line of replacement heart valves made by Edwards Lifesciences (NYSE:EW) are slated to be used to back bids for expanded indications in intermediate-risk patients. Presented over the weekend at the American College of Cardiology’s annual meeting in Chicago, results from the Partner II trial involving the Sapien XT and Sapien […]
Boston Scientific’s Watchman misses 1 of 2 efficacy goals in PREVAIL trial
Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.
ACC14: The quickening pace of change
I just returned from the American College of Cardiology and wanted to write down a few of my 50,000-foot impressions from the meeting for, as the song goes, the times, they are a-changin’.
ACC 2014: Conflicts in renal denervation, competition in valves
The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.
Looking back on a pretty sedate ACC
Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.
